This common molecule could reverse muscle ageing and prevent frailty, scientists say
A common molecule found in the body could be targeted to turn aged muscle cells to become young again, helping prevent frailty in older people, a new study suggests.
The populations of developed countries are getting older, leading to higher rates of associated frailty and debilitation among their people.
Gradual muscle loss in these populations is accelerated by the poor capacity of muscle tissues in older people to repair injury, especially after falls or surgeries.
This leads to a condition called sarcopenia, or low muscle mass, in older people, making them prone to even more frailty and movement problems.
Previous studies have shown that muscle stem cells play a key role in repairing such tissue damage, but they become dysfunctional with age.
Researchers have been trying to understand how aged stem cells differ from young ones and to find ways to reverse these changes.
A new study, published in the journal Cell Stem Cell, reveals that aged mice treated with a naturally occurring molecule in the body called Prostaglandin E2 (PGE2) show improved regeneration and strength of aged muscle.
Scientists also found that the PGE2 molecule works by counteracting stem cell ageing.
In the study, researchers examined the effects of PGE2 and its related molecule EP4 on the body.
Previous research has shown that during muscle injury, PGE2 triggers muscle stem cells to regenerate the muscles of young mice.
In aged mice, scientists found that the EP4 production in muscle stem cells was either lacking, or reduced by half compared to levels found in young stem cells.
'PGE2 is an alarm clock to wake up the stem cells and repair the damage. Aging essentially reduces the volume of the alarm and the stem cells have also put on ear plugs,' said study author Yu Xin Wang.
The new research has found a way to reset the intensity of this cellular alarm clock.
When scientists gave a stable form of PGE2 to aged mice after muscle injury and in conjunction with exercise, they found that the treated mice gained more muscle mass and were stronger compared to untreated ones.
'What amazes me most is that a single dose of treatment is sufficient to restore muscle stem cell function, and that the benefit lasts far beyond the duration of the drug,' Dr Wang said.
'In addition to making new muscle, the stem cells stay in the tissue, where they sustain the effect of the PGE2 and instil the muscle with further capacity to regenerate,' he said.
The study found that PGE2 treatment can restore stem cell function and reverse many of the age-related changes in mice muscles.
'PGE2 has been implicated in the regenerative process and signalling for the intestine, liver, and several other tissues, potentially opening up an approach that could restore the renewing capacity of other aged tissues,' Dr Wang said.
'We have discovered that the PGE2 induces rejuvenation of aged muscle stem cells, which leads to functional improvements in muscle repair and strength,' scientists concluded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
Heart Arrhythmia After COVID-19 Vaccine: A Very Rare Side Effect
Arrhythmia is not a known side effect of COVID-19 vaccines. But ongoing monitoring has shown rare instances of heart complications in people who have received the Pfizer-BioNTech or Moderna mRNA vaccines. Arrhythmia affects the rate or rhythm at which the heart beats. Your heart might beat too fast (tachycardia), too slow (bradycardia), too early (premature contraction), or erratically (fibrillation). Arrhythmia can also be a sign of myocarditis, or inflammation of the heart muscle. Myocarditis is a very rare side effect of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines. You're more likely to experience arrhythmia or myocarditis caused by COVID-19 itself than from the COVID-19 vaccine. At least 2 out of every 10 people hospitalized with COVID-19 experience heart problems, including damage to their heart muscle and arrhythmia. This is what scientists mean when they say the benefits of vaccination outweigh the risks. Keep reading to learn more about heart arrhythmia and myocarditis following COVID-19 vaccination. What the research says Data from the Centers for Disease Control and Prevention (CDC) shows that higher than normal cases of heart inflammation have been reported in the United States after COVID-19 vaccination with the Pfizer-BioNTech or Moderna vaccines. These heart issues occurred mostly in males between ages 12 and 39 after they received the second dose of the vaccine, usually within a few days of receiving the vaccine. This side effect hasn't been observed in people who received the Johnson & Johnson vaccine or the Novavax protein subunit vaccine. The Pfizer-BioNTech and Moderna vaccines are messenger RNA (mRNA) vaccines. These vaccines contain genetically engineered mRNA that teaches your cells how to create antibodies capable of fighting the coronavirus that causes COVID-19. Traditional vaccines, like the Johnson & Johnson COVID-19 vaccine, contain genetic material from the virus, which also helps your body create antibodies. A 2021 analysis of CDC data found that people ages 12 to 39 who received their second COVID-19 mRNA vaccine had about a 13 in 1 million chance of experiencing heart inflammation. In other words, this side effect is exceedingly rare. Another 2021 study involved people ages 16 and up who were vaccinated against COVID-19. It also found slightly increased risks of heart inflammation after participants' first and second doses of COVID-19 vaccines in the first 28 days after vaccination. This research included the Oxford-AstraZeneca vaccine as well as the Pfizer-BioNTech and Moderna vaccines. This risk of myocarditis did appear to be a bit higher after a second dose of the Moderna vaccine — not the other vaccines studied — and was only observed in people younger than 40. Vaccination for people with preexisting heart conditions Even though arrhythmias are sometimes associated with myocarditis, no direct association was found between arrhythmia and COVID-19 vaccination. The American Heart Association recommends that anyone with heart disease get vaccinated against COVID-19 as soon as possible. This is because they're at a much greater risk of heart-related complications from the coronavirus than they are from any COVID-19 vaccine. However, if you or your child has experienced myocarditis after a vaccine before, discuss your options with your doctor before getting vaccinated. What are the symptoms of heart arrhythmia? Arrhythmia doesn't always cause symptoms — that's why you'll sometimes hear it called 'asymptomatic.' But possible symptoms can include: chest pain shortness of breath feeling like the heart is fluttering or pounding (palpitations) rapid heartbeat slow or irregular heartbeat A 2021 study suggests that most people suspected to have myocarditis after COVID-19 experienced chest pain about 2 or 3 days after the second dose of a COVID-19 mRNA vaccine. Arrhythmia during COVID-19 Arrhythmias are more often seen after developing COVID-19 than after vaccination. In small studies conducted in Wuhan, China, during the initial outbreak of COVID-19, arrhythmias occurred at a rate of 16.7% of people hospitalized with COVID-19, with 44.4% of those who were hospitalized being treated in the intensive care unit (ICU). A retrospective 2021 study of 3,970 COVID-19 admissions at Mount Sinai Hospital in New York City found that atrial fibrillation and atrial flutter (AF/AFL) happened in 10% of study participants. AF/AFL was also associated with a 46% higher risk of death — compared with 26% of study participants who had no arrhythmias. Viral infection is the most common cause of inflammation in the heart muscle in children. Children who develop myocarditis after COVID-19 also typically experience a more severe case than if it happens after a COVID-19 vaccination. Heart complications can occur even after you recover from COVID-19. Common vaccine side effects Heart problems are a very rare side effect of COVID-19 vaccines. More common side effects are mild and temporary, including: fever pain and soreness at injection site fatigue headache chills body aches These side effects occur as the vaccine triggers a response from your immune system. In other words, these side effects mean the vaccine is doing its job. Is the COVID-19 vaccine still effective? When first studied in earlier coronavirus variants, COVID-19 vaccines were shown to be roughly: 95% effective at preventing coronavirus infection 94% effective at preventing COVID-19 hospitalizations and deaths among fully vaccinated adults Yet viruses constantly change. Several new variants have emerged since the novel coronavirus first appeared. But even though the first COVID-19 vaccines aren't as effective at preventing infection by the Delta or Omicron variants, they offer significant protection against these variants by reducing your risk of: severe illness hospitalization death Research published in 2022 estimates that COVID-19 vaccines are still up to 90% effective at preventing severe outcomes of COVID-19, including the need for invasive mechanical ventilation or death. People who are fully vaccinated and received a third booster had the highest level of protection against severe disease and hospitalization. Newer boosters have since been developed. Who should get a COVID-19 vaccine? Under the new administration, the CDC recommends that most people ages 18 years and older get an annual COVID-19 vaccine, while those 6 months to 17 years old and pregnant people make a personal decision with their loved ones. However, the American Academy of Pediatrics (AAP) recommends vaccination for every child 6 months or older, and the American College of Obstetricians and Gynecologists (ACOG) recommends vaccination for all pregnant people.
Medscape
an hour ago
- Medscape
DMD Gene Therapy Elevidys Halted After Second Patient Death
Sarepta Therapeutics has temporarily suspended use of the gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy (DMD) after a second patient taking the drug died from acute liver failure, the company announced in a statement. The first death — a teenage boy who also died from acute liver failure after receiving Elevidys — was reported by the company in March. Both deaths occurred in non-ambulatory individuals with DMD. 'Sarepta is temporarily suspending shipments of Elevidys for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place,' the company wrote. 'For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after Elevidys infusion, along with post-treatment monitoring, remains the same,' Sarepta advised. 'In the commercial setting, non-ambulatory patients should no longer receive Elevidys. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted,' Roche, who partners with Sarepta to commercialize Elevidys outside the US, said in a separate statement. The second patient death has also prompted Sarepta to pause dosing in the ENVISION clinical study, a global, randomized, placebo-controlled trial evaluating Elevidys in ambulatory and non-ambulatory patients with DMD aged 8-17 years. ENVISION is the confirmatory trial required under the FDA's accelerated approval pathway for non-ambulatory patients. The trial is already on a temporary clinical hold in Europe. The pause will allow the company to evaluate a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA, Sarepta said in the statement. The FDA will approve the changes before screening and dosing in ENVISION can resume. 'We are taking immediate, decisive steps to better understand and mitigate the risk of acute liver failure, including enhancing the immunosuppressive regimen, for those with Duchenne who are non-ambulatory,' Louise Rodino-Klapac, PhD, Sarepta's chief scientific officer and head of research and development, said in the statement. Globally, more than 900 patients with DMD have been treated to date with Elevidys, including approximately 140 non-ambulatory patients. DMD is a rare, genetic, muscle-wasting disease that primarily affects males and progresses rapidly from early childhood. In June 2023, the US FDA granted accelerated approval to Elevidys, the first gene therapy designed to address the underlying genetic cause of DMD. Elevidys is a one-time treatment administered through a single intravenous dose. Initial approval was for children aged 4-5 years with DMD and a confirmed mutation in the DMD gene. In June 2024, Peter Marks, MD, PhD, then director of the FDA's Center for Biologics Evaluation and Research, unilaterally gave final expanded approval to Elevidys for DMD.
CBS News
2 hours ago
- CBS News
University of Maryland Medical System files $15 million lawsuit over denied health service claims
The University of Maryland Medical System has filed a lawsuit against Physicians Care MCO, accusing the company of improperly denying $15 million in claims for health services. Physicians Care MCO is one of four companies that manages Medicare claims for the state. The UMMS says the company denied claims to 15,000 lower-income patients who use Medicaid. This group of patients includes individuals who were infected with COVID-19, and premature babies treated in neonatal intensive care units, according to the lawsuit. According to the lawsuit, Physicians Care MCO denied claims in a way that violated federal and state laws, as well as its contract with the health system. The UMMS said the company engaged in a "longstanding, ongoing, deliberate, and systematic practice of denying timely and complete payment." Lawsuit details claims of wrongful denial of coverage The lawsuit details multiple examples of what the UMMC says was unlawful denial of coverage. According to the lawsuit, MPC decided that a patient no longer needed to stay in the hospital, despite having recently survived cardiac arrest and a gunshot wound, because their level of pain was deemed too low to warrant continued care. In another case, the suit alleges that MPC denied coverage to a patient with multiple active medical conditions including a recent stroke, HIV, COVID-19, and sepsis - while that patient was still fighting to stabilize. In one example the UMMC said the company declined coverage to a premature infant that was exposed to fentanyl and cocaine in utero. The infant was diagnosed with extreme respiratory distress, recurrent apnea, severe feeding intolerance, and numerous other comorbidities associated with extreme prematurity, according to the lawsuit. "These denials were not just inappropriate—they were cruel. They demonstrate that MPC's corporate profit motives override the medical needs of the sickest and smallest patients in the State," the UMMS wrote. The Baltimore Banner reached out to Physicians Care MCO, but a response has not yet been received.
